Ying Hou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ying Hou has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Hequn Li
Department of Oncology, Nanjing Lishui People's Hospital & Zhongda Hospital Lishui Branch, Southeast University, Nanjing, China
1 shared publicationHui Jia
Department of Ultrasound, Nanjing Lishui People's Hospital & Zhongda Hospital Lishui Branch, Southeast University, Nanjing, China
1 shared publicationHui Xu
Department of Oncology, Nanjing Lishui People's Hospital & Zhongda Hospital Lishui Branch, Southeast University, Nanjing, China
1 shared publicationJiaxing Sun
Department of Radiation Therapy, Nanjing Lishui People's Hospital & Zhongda Hospital Lishui Branch, Southeast University, Nanjing, China
1 shared publicationLei Zhang
Department of Radiation Therapy, Nanjing Lishui People's Hospital & Zhongda Hospital Lishui Branch, Southeast University, Nanjing, China
1 shared publicationRenmin Zhang
Department of Radiation Therapy, Nanjing Lishui People's Hospital & Zhongda Hospital Lishui Branch, Southeast University, Nanjing, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 14 (1) , 626-639
Exploration of key pathogenic mechanisms and potential intervention targets of the traditional Chinese medicine Coptis chinensis in the treatment of cervical cancer based on network pharmacology and molecular docking techniques
Background: Traditional Chinese medicine (TCM) has shown potential in the treatment of cancer. This study investigated the molecular targets and mechanisms of Coptis chinensis in the treatment of cervical cancer using network pharmacology and bioinformatics. Methods: Effective Coptis chinensis components were screened from the Traditional Chinese Medicine Systems Pharmacology (TCMSP) platform based on the following criteria: drug-like properties (DLP) ≥0.18 and oral bioavailability (OB) ≥30%. Target genes were identified through DrugBank, while differentially expressed genes (DEGs) related to cervical cancer were sourced from the Gene Expression Omnibus (GEO) database (GSE7803) based on the following criteria: |log fold change| >2 and PResults: In total, 10 effective Coptis chinensis compounds and 181 target genes were identified from the TCMSP database. The GEO analysis of GSE7803 identified 109 DEGs. The Venn diagram analysis identified the following seven shared DEGs: AR, MAOB, CDKN2A, TOP2A, CXCL8, matrix metalloproteinase 1 (MMP1), and SPP1. MMP1 and SPP1 were confirmed to be upregulated candidate genes in cervical cancer tissues, and to be associated with a worse prognosis [overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI), PMMP1 expression was significantly decreased in the peripheral blood of patients receiving conventional chemotherapy and Coptis chinensis compared to those receiving chemotherapy alone. Multivariate Cox regression confirmed that high MMP1 expression and a lack of Coptis chinensis treatment were independent risk factors for a poor prognosis (PConclusions: MMP1 could be a predictive biomarker for cervical cancer. Coptis chinensis may exert therapeutic effects through MMP1 regulation via multiple pathways. Our findings provide a theoretical foundation for the clinical application of MMP1.
- 1 January 2025
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 14 (1) , 626-639
Open AccessExploration of key pathogenic mechanisms and potential intervention targets of the traditional Chinese medicine Coptis chinensis in the treatment of cervical cancer based on network pharmacology and molecular docking techniques
Background: Traditional Chinese medicine (TCM) has shown potential in the treatment of cancer. This study investigated the molecular targets and mechanisms of Coptis chinensis in the treatment of cervical cancer using network pharmacology and bioinformatics. Methods: Effective Coptis chinensis components were screened from the Traditional Chinese Medicine Systems Pharmacology (TCMSP) platform based on the following criteria: drug-like properties (DLP) ≥0.18 and oral bioavailability (OB) ≥30%. Target genes were identified through DrugBank, while differentially expressed genes (DEGs) related to cervical cancer were sourced from the Gene Expression Omnibus (GEO) database (GSE7803) based on the following criteria: |log fold change| >2 and PResults: In total, 10 effective Coptis chinensis compounds and 181 target genes were identified from the TCMSP database. The GEO analysis of GSE7803 identified 109 DEGs. The Venn diagram analysis identified the following seven shared DEGs: AR, MAOB, CDKN2A, TOP2A, CXCL8, matrix metalloproteinase 1 (MMP1), and SPP1. MMP1 and SPP1 were confirmed to be upregulated candidate genes in cervical cancer tissues, and to be associated with a worse prognosis [overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI), PMMP1 expression was significantly decreased in the peripheral blood of patients receiving conventional chemotherapy and Coptis chinensis compared to those receiving chemotherapy alone. Multivariate Cox regression confirmed that high MMP1 expression and a lack of Coptis chinensis treatment were independent risk factors for a poor prognosis (PConclusions: MMP1 could be a predictive biomarker for cervical cancer. Coptis chinensis may exert therapeutic effects through MMP1 regulation via multiple pathways. Our findings provide a theoretical foundation for the clinical application of MMP1.